Analysts Anticipate Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to Announce -$1.30 Earnings Per Share

Equities analysts forecast that Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) will announce ($1.30) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Mirum Pharmaceuticals’ earnings, with estimates ranging from ($1.47) to ($1.03). Mirum Pharmaceuticals posted earnings of ($1.68) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 22.6%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Mirum Pharmaceuticals will report full year earnings of ($5.01) per share for the current year, with EPS estimates ranging from ($6.01) to ($4.21). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.48) to ($2.54). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) last released its earnings results on Wednesday, March 9th. The company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.31). The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $76.60 million.

A number of brokerages have recently commented on MIRM. SVB Leerink increased their price target on shares of Mirum Pharmaceuticals from $42.00 to $46.00 and gave the stock an “outperform” rating in a report on Friday, January 28th. Raymond James upped their price objective on shares of Mirum Pharmaceuticals from $70.00 to $74.00 and gave the company a “strong-buy” rating in a research note on Friday, March 11th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $49.60.

Shares of NASDAQ:MIRM opened at $27.50 on Friday. The company’s fifty day moving average price is $23.15 and its 200-day moving average price is $18.62. The firm has a market capitalization of $872.58 million, a price-to-earnings ratio of -9.93 and a beta of 1.40. Mirum Pharmaceuticals has a one year low of $12.82 and a one year high of $28.65.

Institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $473,000. Two Sigma Investments LP boosted its position in Mirum Pharmaceuticals by 65.3% during the 3rd quarter. Two Sigma Investments LP now owns 155,275 shares of the company’s stock valued at $3,093,000 after buying an additional 61,360 shares during the period. Wellington Management Group LLP boosted its position in Mirum Pharmaceuticals by 5.4% during the 3rd quarter. Wellington Management Group LLP now owns 364,700 shares of the company’s stock valued at $7,265,000 after buying an additional 18,700 shares during the period. Russell Investments Group Ltd. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $606,000. Finally, GSA Capital Partners LLP boosted its position in Mirum Pharmaceuticals by 26.0% during the 3rd quarter. GSA Capital Partners LLP now owns 39,708 shares of the company’s stock valued at $791,000 after buying an additional 8,193 shares during the period. 78.82% of the stock is owned by institutional investors and hedge funds.

About Mirum Pharmaceuticals (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

See Also